



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

FEBRUARY 16, 2021

PTAS

NIKKI NOMURA
1 DNA WAY, MS-49
C/O GENENTECH, INC.
SOUTH SAN FRANCISCO, CA 94080

506493523

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 02/08/2021

REEL/FRAME: 055258/0523
NUMBER OF PAGES: 37

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: P34753-US/US-1/US-2/W0

ASSIGNOR:

LIN, WEIYU

DOC DATE: 04/22/2020

ASSIGNOR:

SPIESS, CHRISTOPH

DOC DATE: 04/22/2020

ASSIGNOR:

SUN, LIPING

DOC DATE: 04/22/2020

ASSIGNOR:

WU, YAN

DOC DATE: 04/22/2020

ASSIGNOR:

CHIU, CECILIA P.C.

DOC DATE: 04/22/2020

ASSIGNOR:

DARBONNE, WALTER CHRISTIAN

DOC DATE: 04/24/2020

ASSIGNOR:

DILLON, MICHAEL ANDREW

DOC DATE: 04/22/2020

ASSIGNEE:
GENENTECH, INC.
1 DNA WAY
SOUTH SAN FRANCISCO, CALIFORNIA
94080-4990

APPLICATION NUMBER: 17119753 FILING DATE: 12/11/2020
PATENT NUMBER: ISSUE DATE:
TITLE: ANTI-LY6G6D ANTIBODIES AND METHODS OF USE

APPLICATION NUMBER: 62948097 FILING DATE: 12/13/2019
PATENT NUMBER: ISSUE DATE:
TITLE: ANTI-LY6G6D ANTIBODIES AND METHODS OF USE

APPLICATION NUMBER: 63119303 FILING DATE: 11/30/2020
PATENT NUMBER: ISSUE DATE:
TITLE: ANTI-LY6G6D ANTIBODIES AND METHODS OF USE

APPLICATION NUMBER: FILING DATE: 12/11/2020
PATENT NUMBER: ISSUE DATE:
PCT NUMBER: US2020064635
TITLE: ANTI-LY6G6D ANTIBODIES AND METHODS OF USE

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6540299

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
WEIYU LIN	04/22/2020
CHRISTOPH SPIESS	04/22/2020
LIPING SUN	04/22/2020
YAN WU	04/22/2020
CECILIA P.C. CHIU	04/22/2020
WALTER CHRISTIAN DARBONNE	04/24/2020
MICHAEL ANDREW DILLON	04/22/2020
RECEIVING PARTY DATA	
Name:	GENENTECH, INC.
Street Address:	1 DNA WAY
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080-4990
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	62948097
Application Number:	63119303
Application Number:	17119753
PCT Number:	US2020064635
CORRESPONDENCE DATA	
Fax Number:	(650)952-9881
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	650-225-2497
Email:	nikkin@gene.com
Correspondent Name:	NIKKI NOMURA
Address Line 1:	1 DNA WAY, MS-49
Address Line 2:	C/O GENENTECH, INC.
Address Line 4:	SOUTH SAN FRANCISCO, CALIFORNIA 94080
ATTORNEY DOCKET NUMBER:	P34753-US/US-1/US-2/WO

CONFIRMATORY ASSIGNMENT

WHEREAS, WeiYu LIN ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on Exhibit A (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("GENENTECH"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns and delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 22 April 2020, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof.



WeiYu LIN

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: US



GENENTECH, INC.

Kelly B. McClellan
Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P34753-US	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	62/948097	13 December 2019

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P34753-US	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	62/948097	13 December 2019
P34753-US-1	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	63/119303	30 November 2020
P34753-US-2	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	17/119753	11 December 2020
P34753-AR	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	P200103463	11 December 2020
P34753-GC	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	GC-41120	11 December 2020
P34753-JP	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	2020-206866	14 December 2020
P34753-TW	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	109143860	11 December 2020
P34753-WO	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	PCT/US2020/064635	11 December 2020

CONFIRMATORY ASSIGNMENT

WHEREAS, **Christoph SPIESS** ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.


The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 22 April 2020, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:



Christoph SPIESS

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: DE (Germany)



GENENTECH, INC.

Kelly B. McClellan
Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P34753-US	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	62/948097	13 December 2019

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P34753-US	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	62/948097	13 December 2019
P34753-US-1	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	63/119303	30 November 2020
P34753-US-2	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	17/119753	11 December 2020
P34753-AR	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	P200103463	11 December 2020
P34753-GC	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	GC-41120	11 December 2020
P34753-JP	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	2020-206866	14 December 2020
P34753-TW	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	109143860	11 December 2020
P34753-WO	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	PCT/US2020/064635	11 December 2020

CONFIRMATORY ASSIGNMENT

WHEREAS, Liping SUN ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on Exhibit A (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("GENENTECH"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 22 April 2020, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:




Liping SUN

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: US



GENENTECH, INC.

Kelly B. McClellan
Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P34753-US	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	62/948097	13 December 2019

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P34753-US	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	62/948097	13 December 2019
P34753-US-1	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	63/119303	30 November 2020
P34753-US-2	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	17/119753	11 December 2020
P34753-AR	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	P200103463	11 December 2020
P34753-GC	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	GC-41120	11 December 2020
P34753-JP	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	2020-206866	14 December 2020
P34753-TW	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	109143860	11 December 2020
P34753-WO	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	PCT/US2020/064635	11 December 2020

CONFIRMATORY ASSIGNMENT

WHEREAS, Yan WU ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on Exhibit A (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("GENENTECH"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.


The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 22 April 2020, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:




Yan WU

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: US



GENENTECH, INC.

Kelly B. McClellan

Assistant General Counsel

Genentech, Inc.

Authorized Corporate Signatory

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P34753-US	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	62/948097	13 December 2019

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P34753-US	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	62/948097	13 December 2019
P34753-US-1	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	63/119303	30 November 2020
P34753-US-2	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	17/119753	11 December 2020
P34753-AR	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	P200103463	11 December 2020
P34753-GC	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	GC-41120	11 December 2020
P34753-JP	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	2020-206866	14 December 2020
P34753-TW	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	109143860	11 December 2020
P34753-WO	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	PCT/US2020/064635	11 December 2020

CONFIRMATORY ASSIGNMENT

WHEREAS, **Cecilia P. C. CHIU** ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 22 April 2020, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:




Cecilia P. C. CHIU

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: CA



GENENTECH, INC.

Kelly B. McClellan

Assistant General Counsel

Genentech, Inc.

Authorized Corporate Signatory

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P34753-US	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	62/948097	13 December 2019

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P34753-US	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	62/948097	13 December 2019
P34753-US-1	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	63/119303	30 November 2020
P34753-US-2	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	17/119753	11 December 2020
P34753-AR	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	P200103463	11 December 2020
P34753-GC	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	GC-41120	11 December 2020
P34753-JP	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	2020-206866	14 December 2020
P34753-TW	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	109143860	11 December 2020
P34753-WO	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	PCT/US2020/064635	11 December 2020

CONFIRMATORY ASSIGNMENT

WHEREAS, Walter Christian DARBONNE ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("GENENTECH"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 24 April 2020, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:



Walter Christian DARBONNE

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: US



GENENTECH, INC.

Kelly B. McClellan

Assistant General Counsel

Genentech, Inc.

Authorized Corporate Signatory

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P34753-US	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	62/948097	13 December 2019

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P34753-US	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	62/948097	13 December 2019
P34753-US-1	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	63/119303	30 November 2020
P34753-US-2	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	17/119753	11 December 2020
P34753-AR	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	P200103463	11 December 2020
P34753-GC	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	GC-41120	11 December 2020
P34753-JP	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	2020-206866	14 December 2020
P34753-TW	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	109143860	11 December 2020
P34753-WO	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	PCT/US2020/064635	11 December 2020

CONFIRMATORY ASSIGNMENT

WHEREAS, Michael Andrew DILLON ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on Exhibit A (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("GENENTECH"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 22 April 2020, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:



Michael Andrew DILLON

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: US



GENENTECH, INC.

Kelly B. McClellan
Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P34753-US	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	62/948097	13 December 2019

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P34753
Genentech File Identifier: Ly6G6D-CD3 bispecific antibodies

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P34753-US	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	62/948097	13 December 2019
P34753-US-1	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	63/119303	30 November 2020
P34753-US-2	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	17/119753	11 December 2020
P34753-AR	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	P200103463	11 December 2020
P34753-GC	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	GC-41120	11 December 2020
P34753-JP	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	2020-206866	14 December 2020
P34753-TW	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	109143860	11 December 2020
P34753-WO	ANTI-LY6G6D ANTIBODIES AND METHODS OF USE	PCT/US2020/064635	11 December 2020